Status:
COMPLETED
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Lead Sponsor:
Human Genome Sciences Inc.
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Eligibility Criteria
Inclusion
- Confirmed advanced solid malignancy
- Life expectancy of at least 3 months
- Age 18 years or older
- Acceptable liver function
- Acceptable renal function
- Acceptable hematologic status
Exclusion
- Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment.
- Received non-investigational agent within 3 weeks before enrollment.
- Progressive CNS involvement including the need of corticosteroids
- Pregnant or breast-feeding women
- Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1
- Known HIV infection
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00708006
Start Date
May 1 2008
End Date
January 1 2012
Last Update
November 7 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Dept. of Medicine-Oncology
Stanford, California, United States, 94305
2
University of Colorado Health Sciences Center
Aurora, Colorado, United States, 80045
3
The Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203